3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 4
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
28
Lymphoma, Large B-Cell, Diffuse
21
Lymphoma
16
Multiple Myeloma
10
Lymphoma, Non-Hodgkin
10
Lymphoma, Follicular
8
Lymphoma, B-Cell
7
Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hodgkin Disease
5
Burkitt Lymphoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms, Plasma Cell
4
Lymphoma, Mantle-Cell
4
Immunoblastic Lymphadenopathy
4
Recurrence
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Primary Effusion
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Plasmablastic Lymphoma
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Metastatic Castration-resistant Prostate Cancer
2
Lymphoma, T-Cell
2
Hematologic Neoplasms
2
Enteropathy-Associated T-Cell Lymphoma
2
Interventions
enzalutamide
5
Docetaxel
3
zimberelimab
1
sacituzumab govitecan
1
quemliclustat
1
olaparib
1
gedatolisib
1
fludrocortisone acetate
1
darolutamide
1
cabazitaxel
1
abiraterone
1
Prednisone
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Prostatic Neoplasms, Castration-Resistant
×
Prednisone
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled